Xyall Closes €7.6M Financing Round to Globally Roll Out Its Unique High-Tech Molecular Pathology Laboratory Solutions

Xyall BV, a next-generation innovator in molecular pathology, led by Guido du Pree, Mike Roele, Reinhold Wimberger, PhD, and the team, has secured an investment of €7.6 million from a consortium led by Capricorn Partners via their Capricorn Healthtech Fund II, alongside existing investors Sioux Technologies, Brabant Development Agency (BOM), Health Investment Partners, and several private investors.

The funding will support the global rollout of Xyall’s Tissector TableTop, an automated tissue dissection system already used in over 15 molecular pathology laboratories across commercial, academic, pharmaceutical, and research institutions in the United States, signaling rising demand for scalable molecular diagnostics automation.

Traditionally manual and error-prone, tissue dissection is being transformed by Xyall through a fully automated workflow combining high-resolution imaging, precise registration, optimized processes, and high-precision robotics.

Introduced in 2023, the Tissector Table Top was designed to solve practical, day-to-day challenges in molecular pathology laboratories. Adoption by leading hospital labs underscores its clinical relevance and operational value.

Guido du Pree, CEO of Xyall, noted that molecular diagnostics are critical in guiding treatment decisions, particularly in oncology. With laboratories under pressure to deliver faster, more accurate results amid a global shortage of specialized staff, deployment in more than fifteen high-standing laboratories signals that a real and urgent need is being met.

In current practice, pathologists manually mark regions of interest on H&E-stained slides, after which technicians visually transfer the markings to dissection slides and scrape tissue for analysis. The workflow is slow, difficult to scale, and increasingly strained by a global shortage of laboratory technicians.

Du Pree added that while PCR and next-generation sequencing have advanced rapidly, selecting tumor tissue for molecular analysis has remained manual, subjective, and imprecise. Xyall’s fully automated tissue dissection aims to bridge the gap between morphological and molecular diagnostics.

Dick Sietses of Capricorn Partners highlighted Xyall’s ability to improve lab efficiency and diagnostic accuracy, particularly in oncology, noting strong growth momentum and global leadership potential.

Monique Dullens of BOM emphasized the technology’s role in advancing accessible, high-quality healthcare, citing growing commercial traction and strengthened investor support to scale global impact.